Raymond James Financial Inc. Takes $1.58 Million Position in InflaRx (NASDAQ:IFRX)

Raymond James Financial Inc. bought a new stake in shares of InflaRx (NASDAQ:IFRX - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund bought 638,092 shares of the company's stock, valued at approximately $1,576,000. Raymond James Financial Inc. owned 1.08% of InflaRx as of its most recent SEC filing.

Separately, Geode Capital Management LLC raised its position in InflaRx by 32.8% during the fourth quarter. Geode Capital Management LLC now owns 48,136 shares of the company's stock valued at $119,000 after buying an additional 11,900 shares during the period. 42.39% of the stock is currently owned by institutional investors and hedge funds.

InflaRx Trading Down 3.3 %

IFRX stock traded down $0.06 during mid-day trading on Tuesday, hitting $1.60. The stock had a trading volume of 484,746 shares, compared to its average volume of 232,031. The stock has a market capitalization of $107.08 million, a price-to-earnings ratio of -1.48 and a beta of 1.57. InflaRx has a 1-year low of $0.82 and a 1-year high of $2.82. The company has a fifty day moving average of $1.21 and a 200 day moving average of $1.83.

InflaRx (NASDAQ:IFRX - Get Free Report) last posted its earnings results on Thursday, March 20th. The company reported ($0.09) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.27) by $0.18. InflaRx had a negative net margin of 33,362.70% and a negative return on equity of 65.98%. As a group, sell-side analysts expect that InflaRx will post -1.04 earnings per share for the current fiscal year.

Analyst Ratings Changes

IFRX has been the topic of a number of research reports. Guggenheim upped their target price on InflaRx from $7.00 to $10.00 and gave the company a "buy" rating in a report on Wednesday, March 26th. HC Wainwright reiterated a "buy" rating and issued a $8.00 price objective on shares of InflaRx in a research note on Friday, March 21st. Finally, Cantor Fitzgerald started coverage on shares of InflaRx in a research note on Tuesday, April 29th. They set an "overweight" rating and a $10.00 target price for the company.

InflaRx Company Profile

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage.